A proposal for clinical trials of COVID-19 treatment using homo-harringtonine.
A proposal for clinical trials of COVID-19 treatment using homo-harringtonine.
复制标题
关于使用高三尖杉酯碱治疗 COVID-19 的临床试验的提案
DOI：
10.1093/nsr/nwaa257
复制
发表时间：
2021-01
影响因子：
20.6
通讯作者：
Wu CI
中科院分区：
文献类型：
--
作者：
Wen HJ;Liu FL;Huang MX;Luo RH;He WB;Feng J;Chen FL;Cai QC;Ma HJ;Yang ZF;Zhou X;Shang Y;Lyu XM;Zhang DY;Xiao F;Shan H;He JX;Zheng YT;Wu CI
一项治疗新冠肺炎的方案于4月发表在《公共科学图书馆》上[1]，该方案基于阻断非常大的病毒蛋白的翻译。自那以后，更多的支持数据大大加强了这一提议。这种名为HHT(高三尖杉酯碱，或奥乙酰克辛)的药物很容易获得，而且价格低廉，因为它自2012年以来一直被批准用于治疗白血病。体外和体内数据清楚地证明了临床试验的计划是正确的。考虑到特定的机制，我们相信适度规模的试验将足以证明或反驳该治疗方案的有效性。然而，这样的试验只在有许多新感染病例的地区可行。这封信是对吴和文[1]的评论，作者范围更广，包括在治疗新冠肺炎患者方面有第一手经验的内科医生和最近发表了关于SARS-CoV-2的病毒学家。我们希望提请国际社会注意这一建议，因为中国几乎没有新的案件进行这样的审判。
A scheme for treating COVID-19 was published in NSR in April [1] based on blocking the translation of very large viral proteins. Since then, additional supporting data have greatly strengthened the proposal. The drug, HHT (homoharringtonine, or omacetaxine), is readily available and inexpensive as it has been approved since 2012 for treating leukemia. The in vitro and in vivo data clearly justify the planning of clinical trials. Given the specificmechanism, we believe a trial of modest scale would be sufficient to prove, or disprove, the efficacy of the treatment scheme. Such trials, however, are only feasible in regions with many new infections. This letter, commenting on Wu and Wen [1], has an expanded authorship that includes physicians with first-hand experience in treating COVID-19 patients and virologists with recent publications on SARS-CoV-2. We wish to bring this proposal to the attentionof the global community as there are few new cases in China for such trials.